genedrive Past Earnings Performance
Past criteria checks 0/6
genedrive has been growing earnings at an average annual rate of 13.1%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been declining at an average rate of 57% per year.
Key information
13.1%
Earnings growth rate
38.2%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | -57.0% |
| Return on equity | -331.9% |
| Net Margin | -1,837.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is genedrive (LON:GDR) In A Good Position To Invest In Growth?
Mar 08
Here's Why We're Watching genedrive's (LON:GDR) Cash Burn Situation
Jul 11We're A Little Worried About genedrive's (LON:GDR) Cash Burn Rate
Aug 30Here's Why genedrive (LON:GDR) Must Use Its Cash Wisely
May 17Is genedrive's (LON:GDR) Share Price Gain Of 252% Well Earned?
Jan 29
Revenue & Expenses Breakdown
How genedrive makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -5 | 1 | 0 |
| 30 Sep 23 | 0 | -5 | 1 | 0 |
| 30 Jun 23 | 0 | -5 | 1 | 0 |
| 31 Mar 23 | 0 | -5 | 1 | 0 |
| 31 Dec 22 | 0 | -5 | 2 | 0 |
| 30 Sep 22 | 0 | -5 | 2 | 0 |
| 30 Jun 22 | 0 | -5 | 2 | 0 |
| 31 Mar 22 | 0 | -4 | 2 | 0 |
| 31 Dec 21 | 0 | -4 | 2 | 0 |
| 30 Sep 21 | 1 | -2 | 2 | 0 |
| 30 Jun 21 | 1 | -1 | 2 | 0 |
| 31 Mar 21 | 1 | -8 | 2 | 0 |
| 31 Dec 20 | 1 | -15 | 2 | 0 |
| 30 Sep 20 | 1 | -17 | 2 | 0 |
| 30 Jun 20 | 1 | -19 | 2 | 0 |
| 31 Mar 20 | 1 | -12 | 2 | 0 |
| 31 Dec 19 | 2 | -5 | 2 | 0 |
| 30 Sep 19 | 2 | -4 | 2 | 0 |
| 30 Jun 19 | 2 | -4 | 2 | 0 |
| 31 Mar 19 | 2 | -5 | 2 | 0 |
| 31 Dec 18 | 2 | -7 | 2 | 0 |
| 30 Sep 18 | 2 | -7 | 2 | 0 |
| 30 Jun 18 | 2 | -7 | 2 | 0 |
| 31 Dec 17 | 1 | -6 | 3 | 0 |
| 30 Sep 17 | 2 | -6 | 3 | 0 |
| 30 Jun 17 | 3 | -7 | 3 | 0 |
| 31 Mar 17 | 6 | -6 | 2 | 0 |
| 31 Dec 16 | 6 | -5 | 2 | 0 |
| 30 Sep 16 | 6 | -6 | 2 | 0 |
| 30 Jun 16 | 5 | -6 | 2 | 0 |
| 31 Mar 16 | 5 | -5 | 2 | 0 |
| 31 Dec 15 | 4 | -5 | 2 | 0 |
| 30 Sep 15 | 4 | -4 | 2 | 0 |
| 30 Jun 15 | 5 | -3 | 2 | 0 |
| 31 Mar 15 | 5 | -3 | 2 | 0 |
| 31 Dec 14 | 5 | -3 | 2 | 0 |
| 30 Sep 14 | 5 | -2 | 2 | 0 |
| 30 Jun 14 | 6 | -2 | 2 | 0 |
| 31 Mar 14 | 5 | -2 | 2 | 0 |
| 31 Dec 13 | 5 | -1 | 2 | 0 |
Quality Earnings: GDR is currently unprofitable.
Growing Profit Margin: GDR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GDR is unprofitable, but has reduced losses over the past 5 years at a rate of 13.1% per year.
Accelerating Growth: Unable to compare GDR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GDR is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).
Return on Equity
High ROE: GDR has a negative Return on Equity (-331.87%), as it is currently unprofitable.